Bispecific antibodies are an engineered class of antibodies and antibody-like proteins that don’t occur naturally. What makes the Abthena bispecifics unique is the ability to bind two different molecules with a single antibody, the company explained in a statement Monday,
This gives them an advantage over naturally-occurring monospecific antibodies in targeting infectious diseases, maximizing payload delivery and improving functional activity toward particularly challenging targets.
Conversely, Abthena bispecifics can also dual target, which allows for the detection or binding of a target cell type with higher specificity.
ImunoPrice has designed a platform to discover the wild-type and fully human components of bispecific antibodies, which means it can generate pairs of bound proteins with antibody backbones and the attributes necessary to bind to molecules.
The Abthena platform meshes with Artemis Intelligence Metadata, which offers rapid turnaround on additional algorithmic outputs regarding therapeutic optimization, stability, affinity and manufacturability of the antibodies.
More broadly, ImmunoPrecise is a full-service antibody discovery company. Its goal is to deliver its clients with therapeutically significant custom antibodies that have the greatest probability of ultimately succeeding in clinical trials.
Contact Andrew Kessel at firstname.lastname@example.org
Follow him on Twitter @andrew_kessel